Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
about
New and emerging disease modifying therapies for multiple sclerosisImmunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisPharmacological treatment for memory disorder in multiple sclerosisImmunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysisNatalizumab for relapsing remitting multiple sclerosisNatalizumab for relapsing remitting multiple sclerosisNatalizumab for induction of remission in Crohn's diseaseNatalizumab for induction of remission in Crohn's diseaseIdentification of targets and new developments in the treatment of multiple sclerosis--focus on cladribineGLANCE: results of a phase 2, randomized, double-blind, placebo-controlled studyNatalizumab: A new treatment for relapsing remitting multiple sclerosisEvaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathyB Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic InterventionsExploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosisThe Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-AnalysisMonoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomesDisease-modifying treatments for multiple sclerosis - a review of approved medicationsOptimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosisNewer therapies for multiple sclerosisNeuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated EntitiesTreatment strategies for multiple sclerosis: When to start, when to change, when to stop?Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of actionLeukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory diseaseMultiple sclerosis-a quiet revolutionRelating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysisShining a light on intestinal trafficMultiple sclerosisBenefits versus risks of latest therapies in multiple sclerosis: a perspective reviewReview article: anti-adhesion therapies for inflammatory bowel diseasePharmacological Approaches to Delaying Disability Progression in Patients with Multiple SclerosisSystematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosisAn update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerationsVedolizumab for inflammatory bowel disease: Changing the game, or more of the same?Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosis.A herpes simplex virus-derived replicative vector expressing LIF limits experimental demyelinating disease and modulates autoimmunityReview of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosisTherapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosisMultiple sclerosis--new treatment modalitiesDesigning biologic selectivity for inflammatory bowel disease--role of vedolizumabNo quiet surrender: molecular guardians in multiple sclerosis brain
P2860
Q22242305-2EFAE765-191A-4E73-9475-124FDD9D334EQ24187126-541F2F1E-9683-4783-9B74-E3D5D4B3B279Q24201735-CDD9B443-2561-4B9A-87FB-07D8A587222BQ24202108-53452FD1-46D5-4925-B031-7186E8E1F06BQ24235861-8E98986A-FAB7-4B82-8433-5499065736ACQ24241982-A52BC9C7-E389-4F4C-B69C-134610C75C2FQ24245190-779EC2E5-7CB4-4346-AF34-F92F60FC62EAQ24246262-3E9C5FA4-80DB-4B5C-9A25-29D6B1CC1191Q24597369-E872F16B-A17D-460D-AC82-96C12EAA1B6DQ24647794-29F81D37-37E1-4EE0-8DBB-32290C16C11AQ24683014-6CE3B29A-D446-45FA-B3F5-E26046EE3106Q24683776-BDC0159D-7353-412A-A9D7-FBA31E90258BQ26770664-FD3DE3E8-08DD-4C82-B01B-AA0724217206Q26770818-0583672E-B647-41AC-8828-C084FE319B32Q26773978-BBBE746E-F9AF-4BF3-A3CC-78F80F29DB98Q26776234-2402AF6D-6209-4F67-8BF0-744B1291BBBCQ26777329-CB3C93EF-5DBA-47A7-94C6-0BD8E4F8CBEFQ26777686-0EE1B9CF-0A4A-4B55-8AE6-8326D7A255A6Q26779900-05C3FA32-84AB-4F9B-A6D5-776AFCA59DC9Q26781389-FF88FBAA-FBD5-4BBC-99CB-9CC49FAD4173Q26798434-AC6AEAE9-F49F-43E9-A959-371CA6CCCD11Q26822611-A499D44D-9AD9-4029-A503-2E60C5B44189Q26822941-BD1D5EFC-5831-4828-96FC-25F7EFD51333Q26826930-A67F010D-8648-4C61-8387-7C4F91174C2BQ26828463-6E3DC4C2-D120-4E3E-B7E7-750EFC758862Q26863227-F2C661A4-817A-40BF-9113-AA9AE8CFD4B9Q26995437-70919B0F-25A5-4386-9994-D05090AEC9B2Q26999417-BE272752-EF16-40A4-ACC5-022BB167D15DQ26999705-5D445A9D-89C9-4627-AD73-918F1D03E291Q27000269-C406D7F9-2B2D-4EB2-9400-F89A2AFBA4D9Q27004079-CC3E7268-B4B7-4334-A618-2D584E389000Q27009769-E70EDEE9-A57A-438A-B2C6-367116BDB35EQ27021612-839DCC17-1292-4799-861F-34F77E96B395Q27312315-5BD0630D-3D37-4F01-B3F8-F654ADD42C20Q27319470-8DB153DE-6A9C-46B6-B006-1DB799F45AE4Q27693249-89DC1BA1-2B2E-40B6-AE70-09D6A9D878C0Q28066677-F2CC15D3-6E8D-4E7E-9E9E-DE6B34669AE9Q28072906-92344934-A88F-404C-8220-D4429AAB6A03Q28083872-43737401-DB5C-4CC8-AF7F-A9D43F64A34AQ28084633-13EC5C18-BE41-4117-A7B0-1466AB9A8C7A
P2860
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
@en
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
@nl
type
label
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
@en
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
@nl
prefLabel
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
@en
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
@nl
P2093
P50
P356
P1476
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
@en
P2093
Alfred W Sandrock
Christian Confavreux
Daniel R Wynn
Ernst-Wilhelm Radue
Frances Lynn
Fred D Lublin
Michael A Panzara
Richard A Rudick
SENTINEL Investigators
William H Stuart
P304
P356
10.1056/NEJMOA044396
P407
P577
2006-03-01T00:00:00Z